Quote this publication Share Print

NINLARO (ixazomib), antineoplastic agent

TRANSPARENCY COMMITTEE OPINION
Opinions on drugs - Posted on Jul 18 2017

Reason for request

Inclusion

Substantial clinical benefit in combination with lenalidomide and dexamethasone in the treatment of multiple myeloma for patients who have  received at least one prior therapy and no clinical benefit demonstrated compared to the lenalidomide and dexamethasone combination

 

  • NINLARO has been granted marketing authorization (MA) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

  • The results of a study with low robustness on primary endpoint (progression-free survival) do not show any clinical benefit from NINLARO combined with lenalidomide and dexamethasone compared to the lenalidomide and dexamethasone combination.

 

 


Actual benefit

Important

-


Improvement in actual benefit

V (absence)

-


Contact Us

Évaluation des médicaments